4Filing Date: Aug 11, 2026

Guardant Health (GH)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001871615-26-000016
Total Value$15.50M
Trades8
Insiders1

Transaction Details

Freeman Chris
Chief Commercial Officer·Direct
Exercise · Acquire
Common Stock
Shares+35.41K
Price$110.49
Total Value$3.91M
Shares Owned After100.79K
Transaction DateAug 10, 2026
Freeman Chris
Chief Commercial Officer·Direct
Exercise · Acquire
Common Stock
Shares+28.19K
Price$28.37
Total Value$799.8K
Shares Owned After128.98K
Transaction DateAug 10, 2026
Freeman Chris
Chief Commercial Officer·Direct
Sell · Dispose
Common Stock
Shares-17.41K
Price$170.24
Total Value$2.96M
Shares Owned After65.37K
Transaction DateAug 10, 2026
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Freeman Chris
Chief Commercial Officer·Direct
Sell · Dispose
Common Stock
Shares-7.37K
Price$168.79
Total Value$1.24M
Shares Owned After118.15K
Transaction DateAug 10, 2026
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Freeman Chris
Chief Commercial Officer·Direct
Sell · Dispose
Common Stock
Shares-35.36K
Price$169.63
Total Value$6.00M
Shares Owned After82.79K
Transaction DateAug 10, 2026
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Freeman Chris
Chief Commercial Officer·Direct
Exercise · Dispose
Stock Option (Right to Buy)Derivative
Shares-28.19K
Price$0.00
Total Value$0
Shares Owned After1.67K
Transaction DateAug 10, 2026
ExpiresDec 13, 2033
Footnotes ▸

This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

Freeman Chris
Chief Commercial Officer·Direct
Sell · Dispose
Common Stock
Shares-3.46K
Price$167.38
Total Value$579.6K
Shares Owned After125.52K
Transaction DateAug 10, 2026
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Freeman Chris
Chief Commercial Officer·Direct
Exercise · Dispose
Stock Option (Right to Buy)Derivative
Shares-35.41K
Price$0.00
Total Value$0
Shares Owned After3.62K
Transaction DateAug 10, 2026
ExpiresAug 2, 2031
Footnotes ▸

This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested.

Post-Transaction Holdings

Freeman Chris · Chief Commercial Officer
SecuritySharesChange
Common Stock100.79K-
Stock Option (Right to Buy)1.67K-63.60K (-97.44%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-08-10 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Guardant Health, Inc. (GH) CIK: 0001576280 --- Reporting Owner --- Name: Freeman Chris CIK: 0001871615 Role: Officer (Chief Commercial Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-08-10 | Code: M (Exercise of derivative) Shares: +35,412 | Price: $110.49 Total Value: $3,912,671.88 Shares Owned After: 100,786 | Ownership: D (Direct) [Transaction #2] Security: Common Stock Date: 2026-08-10 | Code: M (Exercise of derivative) Shares: +28,193 | Price: $28.37 Total Value: $799,835.41 Shares Owned After: 128,979 | Ownership: D (Direct) [Transaction #3] Security: Common Stock Date: 2026-08-10 | Code: S (Open market sale) Shares: -3,463 | Price: $167.38 Total Value: $579,638.67 Shares Owned After: 125,516 | Ownership: D (Direct) Footnotes: [F1] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. [Transaction #4] Security: Common Stock Date: 2026-08-10 | Code: S (Open market sale) Shares: -7,365 | Price: $168.79 Total Value: $1,243,144.98 Shares Owned After: 118,151 | Ownership: D (Direct) Footnotes: [F2] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. [Transaction #5] Security: Common Stock Date: 2026-08-10 | Code: S (Open market sale) Shares: -35,364 | Price: $169.63 Total Value: $5,998,926.17 Shares Owned After: 82,787 | Ownership: D (Direct) Footnotes: [F3] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. [Transaction #6] Security: Common Stock Date: 2026-08-10 | Code: S (Open market sale) Shares: -17,413 | Price: $170.24 Total Value: $2,964,401.31 Shares Owned After: 65,374 | Ownership: D (Direct) Footnotes: [F4] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Derivative Transactions --- [Transaction #1] Security: Stock Option (Right to Buy) Date: 2026-08-10 | Code: M (Exercise of derivative) Shares: -35,412 | Price: $0.00 Exercisable: N/A | Expires: 2031-08-02 Shares Owned After: 3,620 | Ownership: D (Direct) Footnotes: [F5] This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested. [Transaction #2] Security: Stock Option (Right to Buy) Date: 2026-08-10 | Code: M (Exercise of derivative) Shares: -28,193 | Price: $0.00 Exercisable: N/A | Expires: 2033-12-13 Shares Owned After: 1,668 | Ownership: D (Direct) Footnotes: [F6] This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. --- Footnotes (Complete Index) --- F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F5: This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested. F6: This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. --- Signature --- /s/ /s/ John G. Saia, as attorney-in-fact for Chris Freeman (2026-08-11)

keid analysis is for reference only and does not constitute investment advice.